HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

trandolapril (Mavik)

Also Known As:
Mavik; 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid; Gopten; Odrik; RU 44570; RU-44570; RU44570; Udrik
Networked: 335 relevant articles (47 outcomes, 152 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Pepine, Carl J: 40 articles (01/2021 - 12/2003)
2. Gong, Yan: 23 articles (01/2021 - 06/2007)
3. Cooper-DeHoff, Rhonda M: 21 articles (01/2021 - 12/2003)
4. Handberg, Eileen M: 15 articles (12/2020 - 12/2003)
5. Cooper-Dehoff, Rhonda M: 14 articles (12/2020 - 07/2005)
6. Messerli, Franz H: 14 articles (01/2016 - 12/2003)
7. Champion, Annette: 12 articles (08/2010 - 01/2007)
8. Johnson, Julie A: 10 articles (01/2019 - 06/2007)
9. Ruggenenti, Piero: 10 articles (01/2019 - 11/2004)
10. Zhou, Qian: 10 articles (11/2009 - 01/2007)

Related Diseases

1. Hypertension (High Blood Pressure)
2. Heart Failure
07/01/1999 - "In the diabetic group, trandolapril reduced the risk of progression to severe heart failure markedly (RR, 0.38 [0.21 to 0.67]), and no significant reduction of this end point was found in the nondiabetic group. "
09/01/1998 - "Thus, whereas the initial systemic vasodilating and inotropic effects did not persist, long-term trandolapril results in sustained neurohormonal modulation, reduced preload, and improved organ perfusion, indicated by a persistent increase in renal blood flow and preservation of renal function in severe heart failure."
01/01/2021 - "Effects of Trandolapril on Structural, Contractile and Electrophysiological Remodeling in Experimental Volume Overload Heart Failure."
06/10/2014 - "Furthermore, among patients in the top quartile of FGF-23 levels, trandolapril significantly reduced cardiovascular death or incident heart failure (hazard ratio: 0.45; 95% confidence interval: 0.28 to 0.72), whereas there was no clinical benefit in the remaining patients (hazard ratio: 1.07; 95% confidence interval: 0.75 to 1.52; p interaction = 0.0039). "
01/01/2005 - "Compared with the placebo group, the trandolapril group had a significantly reduced risk of all-cause mortality (relative risk 0.89, 95% CI 0.80-0.99, P=0.03), all-cause hospitalizations (rate ratio 0.92, 95% CI 0.88-0.96, P<0.001), and cardiovascular hospitalizations (rate ratio 0.95, 95% CI 0.91-1.00, P=0.047), including congestive heart failure hospitalizations (rate ratio 0.85, 95% CI 0.77-0.93, P<0.001). "
3. Myocardial Infarction
4. Essential Hypertension
5. Left Ventricular Dysfunction

Related Drugs and Biologics

1. Verapamil (Calan)
2. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
3. Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
4. Antihypertensive Agents (Antihypertensives)
5. Hydrochlorothiazide (Esidrix)
6. Calcium
7. Losartan (Cozaar)
8. Calcium Channel Blockers (Blockers, Calcium Channel)
9. Enalapril
10. Insulin (Novolin)

Related Therapies and Procedures

1. Therapeutics
2. Aftercare (After-Treatment)
3. Surgical Instruments (Clip)
4. Nephrectomy
5. Oral Administration